| To discuss thrombogenesis risk in patients with coronaryatherosclerotic heart disease of different TCM Syndromes and provide advice for clinical treatment. Methods:The patients (n=173) were chosen and divided into CHD of phlegm and blood stasis group (TYHZ group, n=51), CHD of qi stagnancy and blood stasis group (QZXY group, n=55), CHD of qi deficiency and blood stasis group (QXXY group, n=42) and CHD of deficiency of both qi and yin group (QYLX group, n=35). All patients were given detection of thromboela stogram and detection of routine haemostatic. Differences in thromboela stogram indexes, coagulation parameters were compared. Results:R level in the four groups were QYLX>QXXY>QZXY>TYHZ,P<0.01; K level in the four groups were QXXY>QYLX, QYLX>QZXY, QYLX>TYHZ, QXXY>QZXY, QXXY>TYHZ, P<0.05; Angle level in the four groups were QZXY>QYLX, TYHZ>QYLX, QZXY>QXXY, TYHZ>QXXY, P<0.05; MA level in the four groups were QZXY>QYLX, TYHZ>QYLX, P<0.05; ADP level in the four groups were QZXY>TYHZ, QZXY>QXXY, P<0.05; PT level in the four groups were QYLX>QXXY, QYLX>QZXY, QYLX＞TYHZ, P<0.05; INR level in the four groups were QYLX>QXXY, QYLX>QZXY, P<0.05; PLT level in the four groups were QXXY>QYLX, QZXY>QYLX, TYHZ>QYLX, TYHZ>QZXY, TYHZ>QYLX, P<0.05; PCT level in the four groups were QXXY>QYLX, YHZ>QYLX, TYHZ>QZXY, TYHZ>QYLX, P<0.05. EPL, LY30, AA, APTT, FIB, PDW, MPV and P LCR showed no significant differences among these four groups, P>0.05. Conclusion:It is significant to evaluate coagulation function of patients with coronaryatheroscleroticheart disease, especially of phlegm and blood stasis, then to apply anti platelet medicine and to employ the blood activating and stasis dispelling herb. This is because these patients are more likely to have thrombogenesis, and it is the effective treatments to reduce the incidence of thrombogenesis. |
